Vitrolife AB (publ) acquires Unisense FertiliTech A/S

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
Vitrolife AB (publ) acquires Unisense FertiliTech A/S

Vitrolife AB has entered into an agreement to acquire all the shares of Unisense FertiliTech A/S (“FertiliTech”), the market leader within the field of embryo monitoring, time-lapse, for IVF. Description of FertiliTech FertiliTech has driven the clinical use of time-lapse imaging for IVF. Their products have been used in more than 200.000 IVF treatments in 47 countries. FertiliTech has its head office in Århus, Danmark. The company was formed in 2003 and has approximately 70 employees. FertiliTech and its subsidiaries had net sales of approximately SEK 94 million in 2013 and reported income before depreciation and amortization (EBITDA) of SEK -25 million. The company has developed and produces and markets the EmbryoScope® time-lapse incubator, which is used for the monitoring of embryos in approximately two thirds of all the IVF cycles in the world where time-lapse technology is used. Description of time-lapse Time-lapse technology makes it possible to study the whole sequence of embryo development in an undisturbed environment. With increased information on embryo development there is greater potential for selecting an embryo that will result in a pregnancy. Time-lapse technology means that a microscope with a camera, which is placed in the incubator where the embryos are being cultivated, takes images at short time intervals. The images are then played as a film that can be analyzed at the clinic and together with the patients. This technology also reduces the problem of the sensitive embryo being subjected to stress during assessment, as without the use of time-lapse technology it must be taken out of the incubator and transferred to a microscope for observation. Time-lapse technology was introduced on the IVF market approximately 5 years ago and is today used in more than 5 percent of all the IVF cycles in the world. Background and rationale Vitrolife has been active in the time-lapse market since 2012 via the product Primo Vision, which has been both developed and manufactured by Vitrolife’s Hungarian subsidiary. Today the time-lapse market for IVF may be divided into two segments depending on the type of solution. The first solution is a specially developed microscope that is placed in the clinic’s existing incubator. Primo Vision is the market leader in this segment. The second solution is a system where the incubator and the microscope have been integrated. EmbryoScope® is the market leader in this segment. By adding EmbryoScope® to Vitrolife’s current time-lapse product range, Vitrolife can offer customers flexible time-lapse solutions on the basis of their needs and requirements. It is expected that the acquisition will make a positive contribution to future product generations, as the combined knowledge of the development teams in Denmark and Hungary can be utilized for future product development. Vitrolife estimates that, after an introductory phase for the new technology on the market, the time-lapse market will grow and in the long term have the potential to become a standard tool in IVF treatment as a result of the improved treatment results and the more efficient procedures enabled by the technology. “On the strength of the knowledge that the acquisition of Primo Vision has generated, we are now ready to take the next step in our time-lapse strategy by acquiring the market leader in the area. Together with the rest of Vitrolife’s product range, this creates an interesting foundation for future growth opportunities,” says Thomas Axelsson, CEO of Vitrolife. “With its global market presence, strong brand and complementary product range, Vitrolife is the right strategic partner for FertiliTech now that we are about to take the next step in our development towards increased sales and profitability,” says Michael K. Reeslev, CEO of FertiliTech. Proforma financial information Combined proforma sales in 2013 for Vitrolife and FertiliTech amounted to SEK 547 million and income before depreciation and amortization (EBITDA) was SEK 90 million. The figures have been translated from DKK to SEK using an average exchange rate of DKK/SEK 1.16 for 2013. The above figures are only intended as an illustration and do not include the effects of synergies, implementation expenses or depreciation and amortization of assets at fair value as a consequence of allocation of the purchase sum for the acquisition. It is expected that the transaction will affect Vitrolife’s EBITDA per share negatively during 2014 and 2015 but contribute positively as from 2016 as a result of increased sales due to the use of Vitrolife’s global market presence and cost synergies. Terms and time schedule The purchase sum amounts on a debt-free basis to 1,980,000 newly issued shares in Vitrolife, in accordance with the authorization from the 2014 Annual General Meeting, and to a cash purchase sum of SEK 90 million. In connection with the acquisition the company’s net debts will be offset against the purchase sum. It is expected that the new share issue will mean a dilution of existing shareholders of approximately 9 percent. An earn-out corresponding to a value of 1,308,656 shares may be paid in addition to the fixed purchase sum. The earn-out will only be paid if certain defined sales objectives for the periods 2015 and 2016 to 2017 are met. Vitrolife will determine whether the earn-out will be paid in shares or in cash. The earn-out only falls due if sales exceed the plan that forms the basis of the acquisition calculation. Vitrolife estimates that the acquisition will be completed during November 2014. Investor and press conference Vitrolife will hold a telephone conference on Thursday November 6 at 10.00 a.m. in connection with the release of the interim report. The acquisition will also be presented on this occasion. The telephone conference will be led by the CEO, Thomas Axelsson, and the CFO, Mikael Engblom. See the company’s website for further details concerning the telephone conference. The acquisition will also be presented at the company’s Capital Markets Day on November 6. Gothenburg November 5, 2014 VITROLIFE AB (publ) Thomas Axelsson, CEO Queries should be addressed to: Thomas Axelsson, CEO, tel 46 31 721 80 01 Mikael Engblom, CFO, tel 46 31 721 80 14 Vitrolife is required to publish the information in this press release in accordance with the Swedish Securities Market Act and/or the Financial Instruments Trading Act. The information was submitted for publication on November 5, 2014 at 08:30 a.m. This is a translation of the Swedish version of the press release. When in doubt, the Swedish wording prevails. ________________________________________________________________________________ _ ________________________________ Vitrolife (http://www.vitrolife.com/en/Corporate/) is an international medical device Group. Vitrolife Fertility (http://www.vitrolife.com/en/Fertility/) product area develops, produces and markets medical devices for assisted reproduction. Work is also carried out to enable the use and handling of stem cells for therapeutic purposes Vitrolife (http://www.vitrolife.com/en/Corporate/) has approximately 240 employees and the company's products are sold in almost 110 markets. The company is headquartered in Gothenburg, Sweden, and there are also offices in USA, Australia, France, Italy, United Kingdom, China, Japan, Hungary and Denmark. The Vitrolife share (http://www.vitrolife.com/en/Corporate/Financial/The-share1/) is listed on NASDAQ OMX Stockholm (http://www.nasdaqomxnordic.com/aktier/shareinformation?Instrument=SSE 1 3469), Small Cap. ________________________________________________________________________________ _ ________________________________ Vitrolife AB (publ), Box 9080, SE-400 92 Göteborg, Sweden. Corporate identity number 556354-3452. Tel: 46 31 721 80 00. Fax: 46 31 721 80 99. E-mail: info@vitrolife.com. Website: www.vitrolife.com/

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Thanksgiving Dog Safety Is a Pet Care Reality Check

Updated Category News Views 0

A crowded Thanksgiving kitchen can turn a well-behaved dog into a scavenger with lousy odds. Camp Bow Wow’s holiday guidance is not pretending the meal itself is the problem; the trouble is that a house full of distracted people, rich food and unsecured trash creates a pile of easy mistakes. For pet owners, that is a fair reminder. For anybody watching the pet-care...

Continue Reading
Peptide Labels Cannot Substitute for Clinical Care

Updated Category News Views 9

A Label Is Not a Care Plan Those three little words, research use only, carry far more weight than a flashy product page would have people believe. The HelloNation article featuring wellness expert Andres Giraldo makes a plain but necessary distinction: a research-use-only, or RUO, label does not turn a peptide into prescribed treatment, and it sure does not establish...

Continue Reading
Washington-to-Asia Advisory Deal Targets Policy Risk

Updated Category News Views 0

Policy bottlenecks are becoming a cost center across Southeast Asia. That is the plain-English backdrop for the strategic partnership announced November 18, 2026, by Beacon Global Strategies and Vriens & Partners. Neither firm is selling a factory, a chip design, or a new energy project. They are selling something companies increasingly cannot afford to improvise: a...

Continue Reading
Spruce Spins Adrenyx En Route to Nasdaq in 2027

Updated Category News Views 206

New Frontiers: Adrenyx Biosciences Takes Shape Well, here's a new chapter in biotech drama. Spruce Biosciences, a name you might have tangled with if you're into tickers like NASDAQ:SPRB, just carved out a niche with the birth of Adrenyx Biosciences. The play? A separate company eyeing the endocrinology space, setting its sights on tackling congenital adrenal hyperplasia...

Continue Reading
Tactical Tomahawk Motor Deal Puts Propulsion in Focus

Updated Category News Views 31

A missile program lives or dies on unglamorous hardware, and solid rocket motors are about as unglamorous as it gets until somebody cannot build enough of them. Raytheon has awarded Ursa Major and Avio USA a joint contract to develop solid rocket motors for the U.S. Navy’s Tactical Tomahawk missile program. That is the whole headline, and it matters more than the thin...

Continue Reading
Insider Risk Makes Human Judgment a Security Priority

Updated Category News Views 127

A badge, a password, and a locked gate can all look reassuring right up until the person holding them starts to crack. Signpost Six's new report, The Psychology of Insider Risk, lands on an uncomfortable truth: the most consequential security weakness may not be a system at all. It may be an employee under strain, in conflict, in debt, making a mistake, or being quietly...

Continue Reading
Google Search Data Sharing Faces a Privacy Reality Check

Updated Category News Views 91

Search queries are messy little confessions, and that is exactly why this case deserves more than a bureaucratic shrug. Woodway Assurance's independent assessment says Google's search-query data could be treated as anonymized for sharing under the Digital Markets Act, but only if the European Commission tightens parts of its July 2026 framework. That is not a clean bill...

Continue Reading
Kawneer’s OptiQ Window Wins a Useful Design Signal

Updated Category News Views 49

Three Nods, One Very Practical Product Claim Windows rarely stir much excitement outside an architect’s specification binder, but Kawneer has put together a respectable run with its OptiQ Offset Fixed/Projected Series Window. On November 18, 2026, the architectural aluminum-systems maker said the product had won in the Windows and Doors category at both the 2026...

Continue Reading
A Decade of Giving: Light the World Initiative's Impact

Updated Category News Views 157

The Red Kiosk Revolution It's not every day that a church initiative pops up in global conversations, but here we are—ten years into the Light the World initiative by The Church of Jesus Christ of Latter-day Saints. What's interesting is how these little kiosks, like silent ambassadors, have become a staple in 145 spots this holiday season, spanning continents. Each...

Continue Reading
Anycubic Pushes Toward a Smoother 3D Printing Ecosystem

Updated Category News Views 46

Friction Is the Enemy in Consumer 3D Printing A printer that makes a beautiful object only after three failed attempts is not a consumer product; it is a weekend argument with plastic. That is the useful lens for Anycubic's Formnext 2026 showing in Frankfurt on November 18. The company is not merely rolling out FDM and resin machines at Booth F01 in Hall 12.0. It is...

Continue Reading

Top 5 Most Recently Viewed Articles

Bioretec's Innovative Annual Report Showcases New Progress

Updated Category News Views 188

Bioretec Ltd's Annual Report Overview Bioretec Ltd has recently published its annual report for 2024, offering insights into the company's growth and achievements over the past year. This report showcases the advancements made in biodegradable orthopedic implants, positioning the company at the forefront of innovative healthcare solutions. Company Highlights Bioretec...

Continue Reading
Market Overview: Asia Stocks See Fluctuations Amid Election Fears

Updated Category News Views 251

Market Dynamics in Asia: A Closer Look In recent trading sessions, Asian stocks demonstrated muted movements in response to an absence of compelling trading signals, while Japanese shares experienced a notable decline driven by impending democratic choices. Investors are particularly focused on the Japanese electoral scene, which is expected to significantly influence...

Continue Reading
TScan Therapeutics Secures $52.5 Million Loan to Support Growth

Updated Category News Views 113

TScan Therapeutics Secures $52.5 Million Loan from Silicon Valley Bank WALTHAM, Mass. — TScan Therapeutics, Inc. (Nasdaq: TCRX), a clinical-stage biotechnology company dedicated to developing innovative therapies for cancer treatment, has announced an exciting milestone. The company has entered into a term loan facility with Silicon Valley Bank (SVB) that offers up to...

Continue Reading
Celebrating Four Years of SpaceX's Starlink Internet Service

Updated Category News Views 385

Four Years of Starlink Connectivity Four years ago, SpaceX, under the visionary leadership of Elon Musk, began its journey in satellite internet services by activating Starlink for its first paying customer. This significant milestone was established on a date that marks the beginning of a transformative era for internet connectivity. Impact of Starlink on Global Internet...

Continue Reading
AllenComm Receives Esteemed Recognition in eLearning Field

Updated Category News Views 167

AllenComm Earns Top Honor for eLearning Localization AllenComm, a prominent player in the realm of innovative learning experiences, has recently been recognized as one of the Top Content Providers for eLearning Localization by a well-regarded industry source. This accolade reflects the company's dedication to delivering high-quality, effective educational solutions that...

Continue Reading